SAM
KIN

Silverback Asset Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Silverback Asset Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-300,000
Closed -$2.75M – 88
2021
Q2 		$2.75M Sell
300,000
-284,653
-49% -$1.66M 0.33% 57
2021
Q1 		$2.91M Sell
584,653
-26,711
-4% -$129K 0.63% 36
2020
Q4 		$2.63M Buy
611,364
+20,819
+4% +$84.7K 0.33% 49
2020
Q3 		$2.53M Buy
590,545
+9,377
+2% +$39.2K 0.53% 45
2020
Q2 		$2.61M Buy
581,168
+54,180
+10% +$242K 0.65% 41
2020
Q1 		$2.11M Sell
526,988
-13,690
-3% -$116K 0.45% 39
2019
Q4 		$4.58M Hold
540,678
– – 0.68% 29
2019
Q3 		$3.7K Buy
540,678
+31,181
+6% +$229K 0.57% 37
2019
Q2 		$4.24M Buy
509,497
+9,497
+2% +$81.9K 0.65% 36
2019
Q1 		$4.58M Buy
500,000
+216,809
+77% +$2.2M 0.78% 33
2018
Q4 		$3.1M Buy
283,191
+134,791
+91% +$1.7M 0.57% 35
2018
Q3 		$2.07M Buy
+148,400
New +$2.01M 0.32% 41

Other funds holding KIN

CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Silverback Asset Management's KIN Position: Q3 2021 in Review

Silverback Asset Management sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 300,000 shares — an estimated $2.75M sold.

Silverback Asset Management first reported a position in KIN in Q3 2018 and held it in 12 quarters. The position peaked at $4.58M in Q4 2019. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.

  • Silverback Asset Management reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Silverback Asset Management sold 300,000 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $2.75M.
  • Silverback Asset Management first reported a position in Kindred Biosciences, Inc. in Q3 2018 and held it in 12 quarters.
  • Silverback Asset Management's Kindred Biosciences, Inc. position peaked at $4.58M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.

Based on Silverback Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.